Quick Answer
Inhibitor Therapeutics, Inc. reported Total Assets of $2.51 million for the year ending 2025.
- Inhibitor Therapeutics, Inc. showed a decrease of -55.9% in Total Assets from 2024 to 2025.
- This data is from Inhibitor Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: $112.00 | Q1 2014: $10.5 thousand | Q2 2014: $300.5 thousand | Q3 2014: $423.1 thousand | Q1 2015: $127.7 thousand | Q2 2015: $2.19 million | Q3 2015: $1.55 million | Q1 2016: $420.6 thousand | Q2 2016: $4.92 million | Q3 2016: $3.86 million | Q1 2017: $2.78 million | Q2 2017: $2.06 million | Q3 2017: $1.31 million | Q1 2018: $1.98 million | Q2 2018: $1.18 million | Q3 2018: $1.83 million | Q1 2019: $1.25 million | Q2 2019: $2.13 million | Q3 2019: $1.48 million | Q1 2020: $397.3 thousand | Q2 2020: $216.4 thousand | Q3 2020: $103.7 thousand | Q1 2021: $138.1 thousand | Q2 2021: $136.5 thousand | Q3 2021: $92.5 thousand | Q1 2022: $61.1 thousand | Q2 2022: $38.5 thousand | Q3 2022: $63.1 thousand | Q1 2023: $10.84 million | Q2 2023: $10.16 million | Q3 2023: $9.61 million | Q1 2024: $7.79 million | Q2 2024: $7.17 million | Q3 2024: $6.45 million | Q1 2025: $4.51 million | Q2 2025: $3.91 million | Q3 2025: $3.14 million.
- Over the full 14 years of available data (2012 to 2025), Inhibitor Therapeutics, Inc.'s Total Assets has grown by 168.2%.
- Historical annual values: Fiscal year 2025: $2.51 million | Fiscal year 2024: $5.69 million | Fiscal year 2023: $8.95 million | Fiscal year 2022: $11.98 million | Fiscal year 2021: $58.8 thousand | Fiscal year 2020: $131.8 thousand | Fiscal year 2019: $900.0 thousand | Fiscal year 2018: $1.23 million | Fiscal year 2017: $768.1 thousand | Fiscal year 2016: $7.34 million | Fiscal year 2015: $885.9 thousand | Fiscal year 2014: $463.0 thousand | Fiscal year 2013: $10.2 thousand | Fiscal year 2012: $936.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: